Dravet syndrome

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Tuesday, November 29, 2022

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Wednesday, November 23, 2022

VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas’ engagement with Bright Minds as Chief Medical Officer has been terminated.

Key Points: 
  • The Company also announces that Dr. Revati Shreeniwas engagement with Bright Minds as Chief Medical Officer has been terminated.
  • A seasoned executive in CNS drug development, Dr. Smith has directed over 50 clinical trials across all stages of development.
  • Its an exciting time to join Bright Minds with the Phase I trial for its lead program, BMB-101, currently underway.
  • Prior to joining Bright Minds, Dr. Smith was Chief Medical Officer at VistaGen Therapeutics, where he led the clinical development of drug candidates in the areas of major depression, social anxiety disorder, and depression through all phases of development.

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, November 14, 2022

MONARCH and ADMIRAL are multi-center, Phase 1/2a studies of children and adolescents who have an established diagnosis of Dravet syndrome.

Key Points: 
  • MONARCH and ADMIRAL are multi-center, Phase 1/2a studies of children and adolescents who have an established diagnosis of Dravet syndrome.
  • Today, the Company provided topline results from the ongoing Phase 1/2a MONARCH and ADMIRAL studies of STK-001.
  • Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
  • Using Stokes proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, November 8, 2022

During the third quarter, we successfully fulfilled several corporate objectives while we reduced quarter-over-quarter expenses," said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid.

Key Points: 
  • During the third quarter, we successfully fulfilled several corporate objectives while we reduced quarter-over-quarter expenses," said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid.
  • Ovid intends to initiate a Phase 1 trial in Q4 2022, following the FDA clearance of the Company's IND application for OV329.
  • Operating expenses were $12.8 million for the quarter ended September30, 2022 and $11.7 million for the same period in 2021.
  • Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science.

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

Retrieved on: 
Thursday, November 10, 2022

To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761.

Key Points: 
  • To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761.
  • The webinar will be broadcast live on the Investors & News section of Stokes website at https://investor.stoketherapeutics.com/ , and can be accessed by following this Link .
  • An archive replay of the webinar will be available for at least 90 days following the event.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.
  • LP659, an oral, selective, centrally acting S1P receptor modulator, for which we have a pre-IND meeting scheduled with the FDA in the fourth quarter of 2022.
  • Third Quarter 2022 Financial Results:
    At September 30, 2022, Longboards cash, cash equivalents and short-term investments were approximately $77.3 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

Cannabis Drugs Market Size to Surpass US$ 2013.42 Billion by 2030 | Exclusive Report by Growth Plus Reports

Retrieved on: 
Thursday, October 6, 2022

The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.

Key Points: 
  • The increased cannabis approvals by regulatory bodies for medicinal use, rising availability of cannabis drugs in online pharmacy, and more and more physicians prescribing cannabis for medical and recreational purposes is driving the global cannabis drugs market.
  • The global cannabis drugs market has been analyzed from three different perspectives brand, application, and region.
  • Download PDF Brochure of Cannabis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/cannabis-drugs-mark...
    The global cannabis drugs market has been divided into four approved brands namely:
    The largest revenue share was accounted for by the Epidiolex brand segment, which dominated the market for cannabis medications and is predicted to increase at the fastest rate over the forecasted period.
  • The prominent players operating in the global cannabis drugs market:

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

Retrieved on: 
Tuesday, September 13, 2022

The past 18 months have been transformative for ProMIS, stated Eugene Williams, ProMIS Chairman and Co-Founder.

Key Points: 
  • The past 18 months have been transformative for ProMIS, stated Eugene Williams, ProMIS Chairman and Co-Founder.
  • We have also continued to expand our strong management team, having added to the team earlier this year Dr. Larry Altstiel as Chief Medical Officer and, in late 2021, Gavin Malenfant as Chief Operating Officer.
  • Gail has a distinguished track record of accomplishments in both large pharma and biotech, and she has invaluable expertise in neurologic disease drug development.
  • I am honored and excited to take on the role of CEO at ProMIS, remarked Gail Farfel.